- Report
- June 2025
- 81 Pages
From €3113EUR$3,450USD£2,705GBP
- Report
- February 2025
- 148 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- February 2025
- 236 Pages
United States
From €7215EUR$7,995USD£6,269GBP
- Report
- September 2024
- 117 Pages
Global
From €4061EUR$4,500USD£3,528GBP
- Report
- April 2021
China
From €2346EUR$2,600USD£2,039GBP
- Report
- September 2025
- 101 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- May 2023
- 92 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- September 2024
- 109 Pages
China
From €1624EUR$1,800USD£1,411GBP
- Report
- September 2024
- 220 Pages
China
From €3610EUR$4,000USD£3,136GBP
The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more
